Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zincula is an approved ophthalmic combination solution developed by Juggat Pharma (a division of Jagdale Industries) for the relief of eye irritation, eye strain, and allergic conjunctivitis. The formulation contains naphazoline, zinc sulfate, boric acid, and sodium chloride. Naphazoline is a sympathomimetic agent that acts as an agonist on alpha-adrenergic receptors, causing vasoconstriction of conjunctival blood vessels to reduce redness and congestion. Zinc sulfate acts as an astringent to precipitate proteins and clear mucus from the outer surface of the eye, while boric acid provides mild antiseptic properties, and sodium chloride maintains isotonicity to soothe and cleanse the eye.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zincula.